Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: A case report

Journal of Medical Case Reports

Volumn 3, Issue , 2009, Pages

  Behler, Caroline M ^a,b   Terrault, Norah A ^a   Etzell, Joan E ^c   Damon, Lloyd E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1 ANTIBODY; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RITUXIMAB;

AGED; ARTICLE; ASIAN AMERICAN; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE CONCENTRATE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATOSPLENOMEGALY; HUMAN; HYPERSPLENISM; LEUKOPENIA; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETICULOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 72449178354     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.4076/1752-1947-3-7335     Document Type: Article

References (15)

1. Pure red-cell aplasia and epoetin therapy. CL Bennett S Luminari AR Nissenson MS Tallman SA Klinge N McWilliams JM McKoy B Kim EA Lyons SM Trifilio DW Raisch AM Evens TM Kuzel GT Schumock SM Belknap F Locatelli J Rossert N Casadevall, N Engl J Med 2004 351 1403 1408 10.1056/NEJMoa040528 15459301
2. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. D Cournoyer EB Toffelmire GA Wells DL Barber BJ Barrett R Delage DL Forrest RF Gagnon EA Harvey P Laneuville BJ Patterson MC Poon GA Posen HA Messner Canadian PRCA Focus Group, J Am Soc Nephrol 2004 15 2728 2734 10.1097/01.ASN.0000140219.28618.9F 15466278
3. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. K Boven S Stryker J Knight A Thomas M van Regenmortel DM Kemeny D Power J Rossert N Casadevall, Kidney Int 2005 67 2346 2353 10.1111/j.1523-1755.2005.00340.x 15882278
4. Epoetin-associated pure red cell aplasia: past, present, and future considerations. JM McKoy RE Stonecash D Cournoyer J Rossert AR Nissenson DW Raisch N Casadevall CL Bennett, Transfusion 2008 48 1754 1762 10.1111/j.1537-2995.2008.01749.x 18482185
5. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. N Casadevall D Cournoyer J Marsh H Messner C Pallister J Parker-Williams J Rossert, Eur J Haematol 2004 73 389 396 10.1111/j.1600-0609.2004.00348.x 15522059
6. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. DT Dieterich R Wasserman N Bräu TI Hassanein EJ Bini PJ Bowers MS Sulkowski, Am J Gastroenterol 2003 98 2491 2499 14638354
7. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. NH Afdhal DT Dieterich PJ Pockros ER Schiff ML Shiffman MS Sulkowski T Wright Z Younossi BL Goon KL Tang PJ Bowers Proactive Study Group, Gastroenterology 2004 126 1302 1311 10.1053/j.gastro.2004.01.027 15131791
8. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. PJ Pockros ML Shiffman ER Schiff MS Sulkowski Z Younossi DT Dieterich TL Wright SH Mody KL Tang BL Goon PJ Bowers G Leitz NH Afdhal PROACTIVE Study Group, Hepatology 2004 40 1450 1458 10.1002/hep.20482 15565613 (Pubitemid 39657021)
9. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. RT Stravitz H Chung RK Sterling VA Luketic AJ Sanyal AS Price A Purrington ML Shiffman, Am J Gastroenterol 2005 100 1415 1419 10.1111/j.1572-0241.2005.41910.x 15929778
10. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. DG Maloney B Smith FR Applebaum, Blood 1996 88 637
11. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. K Narra H Borghaei T Al-Saleem M Hoglund MR Smith, Leuk Res 2006 30 109 114 10.1016/j.leukres. 2005.05.017 16043218
12. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. HW Auner A Wolfler C Beham-Schmid D Strunk W Linkesch H Sill, Br J Haematol 2002 116 727 728 10.1046/j.1365-2141.2002.3317-3.x 11879264
13. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. M Mandreoli C Finelli A Lopez S Ascani N Vianelli M Baccarani A Santoro, Am J Kidney Dis 2004 44 757 761 10.1016/S0272-6386(04)00948-5 15384028
14. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. D Verhelst J Rossert N Casadevall A Kruger KU Eckardt IC Macdougall, Lancet 2004 363 1768 1771 10.1016/S0140-6736(04)16302-2 15172775 (Pubitemid 38698380)
15. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. CL Bennett D Cournoyer KR Carson J Rossert S Luminari AM Evens F Locatelli SM Belknap JM McKoy EA Lyons B Kim R Sharma S Costello EB Toffelmire GA Wells HA Messner PR Yarnold SM Trifilio DW Raisch TM Kuzel A Nissenson LC Lim MS Tallman N Casadevall, Blood 2005 106 3343 3347 10.1182/blood-2005-02-0508 16099877